Peripheral site of action of levodropropizine in experimentally-induced cough: role of sensory neuropeptides.
The mechanism of action of levodropropizine has been investigated in different models of experimentally-induced cough in guinea-pigs. In particular it has been demonstrated that the antitussive drug has a peripheral site of action by injecting the drug intracerebroventricularly (i.c.v.). In these experiments levodropropizine (40 micrograms/50 microliters i.c.v.) did not prevent electrically-induced cough. On the other hand, codeine (5 micrograms/50 microliters i.c.v.) markedly prevented coughing. A difference in the potency ratio of levodropropizine and codeine has been demonstrated in capsaicin-induced cough; after oral administration, codeine was about two to three times more potent than levodropropizine. However, after aerosol administration the two compounds were equipotent. These data might suggest a peripheral site of action for levodropropizine which is related to sensory neuropeptides. Further support for the role of sensory neuropeptides in the mechanism of action of levodropropizine comes from the results obtained in capsaicin-desensitized animals. In this experimental model levodropropizine failed to prevent the vagally elicited cough in neuropeptide-depleted animals, whereas codeine did not differentiate between control and capsaicin-treated animals. In conclusion, our results support the suggestion that levodropropizine has a peripheral site of action. In addition, the interference with the sensory neuropeptide system may explain, at least in part, its activity in experimentally-induced cough.
Lavezzo
A
A
Dompé Research and Development Laboratories, Dompé Farmaceutici S.p.A., Milan, Italy.
Melillo
G
G
Clavenna
G
G
Omini
C
C
D000818:Animals; D000996:Antitussive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002211:Capsaicin / Q000633:toxicity; D003061:Codeine / Q000008:administration & dosage / Q000627:therapeutic use*; D003371:Cough / Q000188:drug therapy* / Q000209:etiology; D004558:Electric Stimulation; D006168:Guinea Pigs; D007276:Injections, Intraventricular; D008297:Male; D009479:Neuropeptides / Q000502:physiology; D011409:Propylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D014630:Vagus Nerve
D000996:Antitussive Agents; D009479:Neuropeptides; D011409:Propylene Glycols; D002211:Capsaicin; C035916:dipropizine; D003061:Codeine